logo
  Join        Login             Stock Quote

AVEO Pharma (AVEO), Astellas Pharma: FDA Accepts NDA Filing Of Cancer Drug Tivozanib

 November 28, 2012 07:51 AM


(By Balaseshan) AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) and Astellas Pharma Inc. say the U.S. Food and Drug Administration (FDA) has accepted of the New Drug Application (NDA) filing for tivozanib to treat advanced renal cell carcinoma.

Tivozanib is an investigational medicine and is not currently approved in any country. According to the timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the NDA is expected to be complete by July 28, 2013.

The FDA's acceptance of the NDA triggers a $15 million milestone payment to AVEO under its development and commercialization agreement with Astellas.

[Related -AVEO: FDA Panel Votes Against Recommending Approval For Kidney Cancer Treatment]

The proposed brand name for tivozanib is Tivopath, which is a trademark of AVEO Pharma. This name has received conditional acceptance from the FDA and the European Medicines Agency (EMA), but final approval by the FDA and EMA is pending. Tivozanib is an investigational compound. Its safety and efficacy have not yet been fully established.

Advanced renal cell carcinoma (RCC), or kidney cancer, is the ninth most commonly diagnosed cancer in men and women in the U.S. Worldwide it is estimated that more than 250,000 people are diagnosed and more than 100,000 people die from the disease each year. RCC accounts for more than 90% of all kidney cancers.

The NDA includes results of the global Phase 3 TIVO-1 (TIvozanib Versus SOrafenib in 1st line Advanced RCC) trial, a randomized superiority-designed pivotal trial evaluating the efficacy and safety of tivozanib compared to sorafenib, an approved targeted agent, in 517 patients with advanced RCC, as well as data from 16 additional AVEO-sponsored studies involving over 1,000 subjects who received tivozanib.

[Related -Why Aveo's Tivozanib Should Win FDA Approval]

Results of TIVO-1 were presented at the 2012 Annual Meeting of the American Society for Clinical Oncology (ASCO). Tivozanib is also under evaluation across a broad range of solid tumors, including metastatic colorectal cancer and metastatic breast cancer.

AVEO closed Tuesday's regular session up 0.14% at $7.11. The stock has been trading between $5.80 and $17.65 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageSanDisk Corporation (SNDK) Q1 Earnings Preview: Heads or Tails on Pop or Drop

SanDisk Corporation (NASDAQ:SNDK) will publish its first quarter 2014 financial results press release via read on...

article imageEstee Lauder Companies Inc (EL): Goldman Sachs is Convicted EL Will Make Your Portfolio Prettier

Want to freshen up your portfolio? Goldman Sachs say to add Estee Lauder Companies Inc (NYSE:EL). The read on...

article imageYahoo! Inc. (YHOO) Q1 Earnings Preview: Another Bullish Surprise Coming

Yahoo! Inc. (NASDAQ:YHOO) will discuss the company's financial results for the first quarter ended March read on...

article imageThe Coca-Cola Company (KO) Q1 Earnings Preview: Guidance About to Fizzle?

The Coca-Cola Company (NYSE:KO) plans to release its first quarter earnings results before the market opens read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.